On October 3, 2024, Kristiina Vuori, Director at Inhibrx Biosciences Inc (INBX, Financial), purchased 6,667 shares of the company, as reported in a recent SEC Filing. Following this transaction, the insider now owns a total of 20,443 shares of Inhibrx Biosciences Inc.
Inhibrx Biosciences Inc is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. The company aims to address unmet medical needs in oncology, orphan diseases, and infectious diseases through its proprietary platforms.
The transaction occurred with shares priced at $15 each, valuing the purchase at approximately $100,005. This acquisition has contributed to a total of 11 insider buys over the past year, with no insider sales reported during the same period.
The current market cap of Inhibrx Biosciences Inc stands at $221.049 million. The stock's price-earnings ratio is notably low at 0.14, compared to the industry median of 27.79, suggesting a potential undervaluation relative to its peers.
This insider buying trend may signal a positive outlook from the insider on the company's current valuation and future prospects. Investors often look at insider transactions as a sign of confidence in the company's future performance.
For more detailed valuation metrics such as GF Value, price-sales ratio, price-book ratio, and price-to-free cash flow, interested parties are encouraged to visit the respective links.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
